Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $4.79 Consensus PT from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned an average rating of “Hold” from the eleven research firms that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $4.79.

Separately, StockNews.com assumed coverage on Marinus Pharmaceuticals in a research report on Wednesday. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Woodline Partners LP lifted its position in shares of Marinus Pharmaceuticals by 84.7% in the fourth quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock worth $1,250,000 after buying an additional 1,071,410 shares in the last quarter. Beryl Capital Management LLC bought a new stake in Marinus Pharmaceuticals in the 4th quarter worth approximately $2,262,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Marinus Pharmaceuticals during the 4th quarter worth approximately $54,000. XTX Topco Ltd boosted its position in shares of Marinus Pharmaceuticals by 1,564.7% during the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 206,614 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Marinus Pharmaceuticals by 266.1% in the fourth quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 354,393 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $0.55 on Monday. The stock has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The firm’s fifty day moving average is $0.55 and its 200 day moving average is $0.73. Marinus Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $9.24.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.